KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Immunogenicity and safety of a bivalent, adjuvant system 04-adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15-25: a randomized, double-blind, phase III, noninferiority clinical trial.

Seyyedeh Maryam Afshani, Reihaneh Mirhassani, Hamed Hosseini, Reihaneh Hosseini, Afsaneh Tehranian, Reza Malekzadeh, Afshin Ostovar, Amir Hossein Abdolghaffari, Mohammad Amin Ghobadi, Behnaz Hedayatjoo, Delara Hazegh Fetratjoo, Zahra Rezagholi, AmirHossein Anari, Ashraf Moini

Eur J Cancer Prev 31(6) 558-567

PMID35352698
PMCID-
DOI10.1097/CEJ.0000000000000753
发表日期2022-03-30
入排依据:The study is a Phase III randomized trial of a drug-containing vaccine intervention in an oncology-related context (HPV prevention for cervical cancer). However, the primary efficacy endpoint is noninferiority based on immunogenicity (GMT ratios and seroconversion rates), not a time-to-event outcome such as OS, PFS, DFS, EFS, RFS, TTP, or any analysis using Kaplan-Meier or reporting a hazard ratio. Therefore, it does not meet the required time-to-event efficacy endpoint criterion for this cohort.
摘要

摘要

OBJECTIVE: Vaccination is proven to significantly reduce the risk of human papillomavirus (HPV)-related complications, especially cervical cancer. This study aimed to assess the immunogenicity and safety of the investigational bivalent HPV vaccine (16/18), named Papilloguard (Noyan Pajouhan Biopharma, Tehran, Iran), in comparison with the reference product (Cervarix, bivalent HPV vaccine (16/18) manufactured by GlaxoSmithKline, Rixensart, Belgium) in a three-dose regimen. METHODS: This trial was a randomized, controlled, double-blind, phase III study of two HPV vaccines in healthy female volunteers aged 15-25. The primary endpoint was to test the noninferiority of Papilloguard (Noyan Pajouhan Biopharma) to Cervarix (GlaxoSmithKline) as measured by the geometric mean titer (GMT) ratios of HPV-16 and HPV-18 7 months after the first vaccination. Secondary endpoints were the proportion of local and systemic solicited and unsolicited events, and the number of females with seroconversion against HPV-16 and HPV-18 7 months after the first vaccination. RESULTS: Out of 504 screened women, 218 were enrolled. Seven months after the first vaccination, GMT ratios of HPV-16 and HPV-18 were 0.59 and 0.93, respectively. The seroconversion rates of both Papilloguard (Noyan Pajouhan Biopharma) and Cervarix (GlaxoSmithKline) were more than 96%. Both vaccinated groups had a generally good profile of solicited and unsolicited adverse events (AEs). The most common AE was discomfort at the injection site, which was well tolerated. CONCLUSION: The result analysis of this study supports the noninferiority of Papilloguard (Noyan Pajouhan Biopharma) to Cervarix (GlaxoSmithKline) in terms of safety and immunogenicity based on the GMT ratio. However, long-term comparative studies to evaluate the sustainability of GMT response and risk of cervical intraepithelial neoplasia grades 2-3 are needed.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。